Motile sperm domain containing protein 2 and inflammation
Inventors
Mendel, Itzhak • Propheta-Meiran, Oshrat • Salem, Yaniv • SHOHAM, Anat • Breitbart, Eyal
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12109264-B2
Publication Date
2024-10-08
Expiration Date
Abstract
Disclosed herein are methods of treating, preventing, or reducing the incidence of an inflammatory disease or disorder and methods of inhibiting, preventing, or reducing the incidence of one or more activities in a cell with an inhibitor of a Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 and pharmaceutical compositions containing MOSPD2 inhibitors.
Core Innovation
The invention is directed to oxidized phospholipids, including oxidized phospholipid structures defined by Formula IIIa, and oxidized phospholipid structures according to Formula V and Formula VI. It specifies substituent groups, including Y as a phosphoryl choline or other phospholipid headgroup, and defines other substituent relationships involving Z, E, F, and oxygen-containing groups including B1/B2/B3. The document further provides preferred oxidized phospholipid examples including 1-hexadecyl-2-(4′-carboxy)butyl-glycero-3-phosphocholine and (R)-enantiomer variants.
MOSPD2, Motile Sperm Domain containing Protein 2, is described as a highly conserved membrane protein and is linked to inflammatory disease processes. The document addresses chronic inflammatory disease or disorder and associates MOSPD2 activity with inflammatory pathways including leukocyte and monocyte migration and chemotaxis, chemokine signaling pathway activity, and signaling such as ERK phosphorylation and AKT phosphorylation.
The core disclosed approach is inhibiting MOSPD2 in a subject using MOSPD2 inhibitors, including small molecules, antibody, RNA silencing agent approaches, and gene editing approaches. In particular, the document emphasizes MOSPD2 inhibitors as an RNA silencing agent for treating chronic inflammatory disease or disorder, with the inhibitor directed to MOSPD2-associated activity.
Claims Coverage
The provided independent claim coverage consists of one independent claim directed to treating chronic inflammatory disease or disorder by administering a MOSPD2 inhibitor, where the inhibitor is an RNA silencing agent. The inventive features are organized around MOSPD2 inhibition and the use of an RNA silencing agent for inflammatory disease treatment.
MOSPD2 inhibition for chronic inflammatory disease treatment
A method of treating a chronic inflammatory disease or disorder in a subject comprising administering to the subject an inhibitor of MOSPD2.
RNA silencing agent MOSPD2 inhibitor
The method wherein the inhibitor is an RNA silencing agent.
Enumerated chronic inflammatory disease indications
The method wherein the chronic inflammatory disease or disorder is rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease, polyarteritis nodosa, polymyositis/dermatomyositis, Sjogren's syndrome, Behcet's disease, multiple sclerosis, autoimmune diabetes, Hashimoto's disease, psoriasis, primary myxedema, pernicious anemia, myasthenia gravis, chronic active hepatitis, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, uveitis, vasculitides, or heparin induced thrombocytopenia.
Across the independent claim, the main inventive content is administering an inhibitor of MOSPD2 to treat chronic inflammatory disease or disorder, with the inhibitor being an RNA silencing agent and with the disease limited to a specific enumerated set.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating a chronic inflammatory disease or disorder in a subject using a MOSPD2 inhibitor that is an RNA silencing agent.
Treatment indications explicitly listed include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease, polyarteritis nodosa, polymyositis/dermatomyositis, Sjogren's syndrome, Behcet's disease, multiple sclerosis, autoimmune diabetes, Hashimoto's disease, psoriasis, primary myxedema, pernicious anemia, myasthenia gravis, chronic active hepatitis, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, uveitis, vasculitides, and heparin induced thrombocytopenia.
Interested in licensing this patent?